Plain-English translation of NCT03604315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging tracer called fluorine F-18 fluorthanatrace, which is a radioactive substance used in PET/CT scans to detect cancer. Researchers believe this medication may help identify cancer cells more effectively by detecting a specific protein called PARP-1 that is often active in cancer. The study will show whether this new imaging method can help doctors better understand and monitor cancer in patients.
Current cancer imaging methods don't always show all the places where cancer is growing or help predict how well treatment will work. This trial is exploring whether the new treatment can provide more detailed information about cancer, which could eventually help doctors choose better treatment options and monitor how well those treatments are working.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive two imaging scans. First, you'll have a standard PET/CT scan using a common imaging tracer (if you haven't already had one recently), which takes 20–30 minutes. Then, at least 20–24 hours later, you'll return for a second scan using the new imaging medication, which takes about 1 hour. You'll also have a follow-up check-in by phone or in person about 24 hours after your final scan to make sure you're doing well.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States